DK2872917T3 - Indretning og fremgangsmåde til bestemmelse af en propposition - Google Patents
Indretning og fremgangsmåde til bestemmelse af en propposition Download PDFInfo
- Publication number
- DK2872917T3 DK2872917T3 DK13735038.5T DK13735038T DK2872917T3 DK 2872917 T3 DK2872917 T3 DK 2872917T3 DK 13735038 T DK13735038 T DK 13735038T DK 2872917 T3 DK2872917 T3 DK 2872917T3
- Authority
- DK
- Denmark
- Prior art keywords
- sound
- container
- sound source
- plug
- exendin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 22
- 239000003814 drug Substances 0.000 claims description 27
- 238000012377 drug delivery Methods 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 15
- 230000010363 phase shift Effects 0.000 claims description 5
- 230000005236 sound signal Effects 0.000 claims 13
- 238000006073 displacement reaction Methods 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 54
- 108010011459 Exenatide Proteins 0.000 description 50
- 229960001519 exenatide Drugs 0.000 description 50
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229940127560 insulin pen Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OIWCYIUQAVBPGV-DAQGAKHBSA-N {1-O-hexadecanoyl-2-O-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}serine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OIWCYIUQAVBPGV-DAQGAKHBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16831—Monitoring, detecting, signalling or eliminating infusion flow anomalies
- A61M5/1684—Monitoring, detecting, signalling or eliminating infusion flow anomalies by detecting the amount of infusate remaining, e.g. signalling end of infusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31568—Means keeping track of the total dose administered, e.g. since the cartridge was inserted
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01F—MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
- G01F17/00—Methods or apparatus for determining the capacity of containers or cavities, or the volume of solid bodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
- G01S15/00—Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems
- G01S15/02—Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems using reflection of acoustic waves
- G01S15/06—Systems determining the position data of a target
- G01S15/08—Systems for measuring distance only
- G01S15/32—Systems for measuring distance only using transmission of continuous waves, whether amplitude-, frequency-, or phase-modulated, or unmodulated
- G01S15/36—Systems for measuring distance only using transmission of continuous waves, whether amplitude-, frequency-, or phase-modulated, or unmodulated with phase comparison between the received signal and the contemporaneously transmitted signal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
- G01S15/00—Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems
- G01S15/88—Sonar systems specially adapted for specific applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3375—Acoustical, e.g. ultrasonic, measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3389—Continuous level detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01F—MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
- G01F11/00—Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it
- G01F11/02—Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it with measuring chambers which expand or contract during measurement
- G01F11/021—Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it with measuring chambers which expand or contract during measurement of the piston type
- G01F11/029—Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it with measuring chambers which expand or contract during measurement of the piston type provided with electric controlling means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01F—MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
- G01F22/00—Methods or apparatus for measuring volume of fluids or fluent solid material, not otherwise provided for
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Radar, Positioning & Navigation (AREA)
- Remote Sensing (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Acoustics & Sound (AREA)
- Computer Networks & Wireless Communication (AREA)
- Fluid Mechanics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
- Length Measuring Devices Characterised By Use Of Acoustic Means (AREA)
- Special Conveying (AREA)
Claims (10)
1. Lægemiddelfremføringsanordning (1) med en beholder (2), der definerer et hulrum (3) til et lægemiddel, og en prop (4) til proksimal afgrænsning af hulrummet (3) og fortrængning af lægemidlet fra hulrummet (3) , hvilken lægemiddelfremføringsanordning (1) yderligere omfatter en indretning til bestemmelse af en position (x) af proppen (4) i forhold til beholderen (2), idet indretningen omfatter en lydkilde (5), der er konfigureret til at udsende et lydsignal, og en lydsensor (6), der er konfigureret til at påvise et lydsignal, en processorenhed (10) til at styre lydkilden (5) og behandle det påviste lydsignal til bestemmelse af egenskaber for lydsignalet, der svarer til positionen (x) af proppen (4), der er kendetegnet ved, at lydkilden (5) er justeret ind, så den sender lydsignalet ind i et resonansvolumen (7), der defineres i én rumlig dimension ved hjælp af positionen af proppen (4), hvor processorenheden (10) er konfigureret til at variere frekvensen (f) af det udsendte lydsignal inden for et forudbestemt frekvensinterval, hvor processorenheden (10) er konfigureret til at påvise en overtone (fi(x), f2 (x) , f3 (x) , £a (x) ) af en resonansfrekvens fk, der er karakteristisk for det resonansvolumen (7), der er forbundet med positionen (x), hvor resonansvolumenet (7) defineres mindst delvist i en proksimal ende af beholderen (2), og/eller hvor en rørdel (9) med i det væsentlige den samme indvendige diameter som beholderen (2) er anbragt proksimalt tilgrænsende til beholderen (2) til mindst delvis definering af resonansvolumenet (7).
2. Indretning ifølge krav 1, der er kendetegnet ved, at lydkilden (5) er justeret ind, så den sender lydsignalet gennem en proksimal åbning i beholderen (2) mod proppen (4), hvor processorenheden (10) er konfigureret til at styre lydkilden (5) til udsendelse af en kodet lydbølge (U) og bestemme en forsinkelse eller et faseskift af den påviste lydbølge, der er forbundet med positionen (x).
3. Indretning ifølge krav 2, der er kendetegnet ved, at lydbølgen (U) er en ultralydbølge (U).
4. Indretning ifølge et af kravene 2 eller 3, der er kendetegnet ved, at lydkilden (5) og lydsensoren (6) er integreret i en lydomformer, der kan skiftes operativt til at fungere som enten lydkilden (5) eller lydsensoren (6).
5. Indretning ifølge krav 1, der er kendetegnet ved, at det forudbestemte frekvensinterval er udvalgt således, at det svarer til mindst en del af et interval af lineær frekvensrespons af lydkilden (5) .
6. Fremgangsmåde til bestemmelse af en position (x) af en prop (4) i forhold til en beholder (2) i en lægemiddelfremføringsanordning (1), hvilken fremgangsmåde omfatter trinene: - udsendelse af et lydsignal fra en lydkilde (5) , påvisning af et lydsignal forårsaget af det udsendte lydsignal ved hjælp af en lydsensor (6), behandling af det påviste lydsignal til bestemmelse af egenskaber for lydsignalet, der svarer til positionen (x) af proppen (4), ved hjælp af en processorenhed (10), der er kendetegnet ved, at lydkilden (5) er justeret ind, så den sender lydsignalet ind i et resonansvolumen (7), der defineres i én rumlig dimension ved hjælp af positionen af proppen (4), hvor frekvensen (f) af det udsendte lydsignal varieres inden for et forudbestemt frekvensinterval, hvor der påvises en overtone (fi(x), f.2 (x) , f3 (x) , f4 (x) ) af en resonansfrekvens f*, der er karakteristisk for det resonansvolumen (7), der er forbundet med positionen (x), hvor resonansvolumenet (7) defineres mindst delvist i en proksimal ende af beholderen (2), og/eller hvor en rørdel (9) med i det væsentlige den samme indvendige diameter som beholderen (2) er anbragt proksimalt tilgrænsende til beholderen (2) til mindst delvis definering af resonansvolumenet (7).
7. Fremgangsmåde ifølge krav 6, der er kendetegnet ved, at lydkilden (5) er justeret ind, så den sender lydsignalet gennem en proksimal åbning i beholderen (2) mod proppen (4), hvor lydkilden (5) styres til udsendelse af en kodet lydbølge (U) , og hvor der bestemmes en forsinkelse eller et faseskift af den påviste lydbølge, der er forbundet med positionen (x).
8. Fremgangsmåde ifølge krav 7, der er kendetegnet ved, at lydbølgen (U) er en ultralydbølge (U).
9. Fremgangsmåde ifølge et af kravene 6 eller 7, der er kendetegnet ved, at lydkilden (5) og lydsensoren (6) er integreret i en lydomformer, der kan skiftes operativt til at fungere som enten lydkilden (5) eller lydsensoren (6).
10. Fremgangsmåde ifølge krav 6, der er kendetegnet ved, at det forudbestemte frekvensinterval er udvalgt således, at det svarer til mindst en del af et interval af lineær frekvensrespons af lydkilden (5) .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12175974 | 2012-07-11 | ||
| PCT/EP2013/064630 WO2014009442A1 (en) | 2012-07-11 | 2013-07-10 | Arrangement and method for determining a stopper position |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2872917T3 true DK2872917T3 (da) | 2016-12-19 |
Family
ID=46934376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13735038.5T DK2872917T3 (da) | 2012-07-11 | 2013-07-10 | Indretning og fremgangsmåde til bestemmelse af en propposition |
| DK16180037.0T DK3112896T3 (da) | 2012-07-11 | 2013-07-10 | Indretning og fremgangsmåde til bestemmelse af en propposition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16180037.0T DK3112896T3 (da) | 2012-07-11 | 2013-07-10 | Indretning og fremgangsmåde til bestemmelse af en propposition |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9592345B2 (da) |
| EP (2) | EP3112896B1 (da) |
| JP (1) | JP6266613B2 (da) |
| CN (2) | CN104428688A (da) |
| DK (2) | DK2872917T3 (da) |
| WO (1) | WO2014009442A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9592345B2 (en) * | 2012-07-11 | 2017-03-14 | Sanofi-Aventis Deutschland Gmbh | Arrangement and method for determining a stopper position |
| DE102012220468B3 (de) * | 2012-11-09 | 2014-03-27 | Seca Ag | Längenmessgerät |
| US9907902B2 (en) * | 2013-12-20 | 2018-03-06 | Maxim Integrated Products, Inc. | Precise accurate measurement of the administration of drugs using the injection method by means of ultrasonic pulse-echo principles |
| JP6141466B2 (ja) * | 2015-09-29 | 2017-06-07 | 株式会社東京精密 | ワーク識別装置及び識別方法 |
| EP3419697B1 (en) | 2016-02-26 | 2024-05-01 | Eli Lilly and Company | Reusable medication delivery device with remaining medication determination capability |
| JP6543775B2 (ja) | 2016-03-25 | 2019-07-10 | イーライ リリー アンド カンパニー | 薬剤送達装置における設定及び送達された用量の判定 |
| WO2017184401A1 (en) | 2016-04-19 | 2017-10-26 | Eli Lilly And Company | Determination of a dose in a medication delivery device using two moving arrays with teeth and a sensor |
| EP3496790B1 (en) | 2016-08-12 | 2020-10-21 | Eli Lilly and Company | Dose sensing mechanism in a medication delivery device |
| US10413676B1 (en) * | 2016-10-24 | 2019-09-17 | Verily Life Sciences Llc | Ultrasound tracking of medication delivery by medication injection devices |
| CA3044858C (en) | 2016-12-15 | 2022-04-26 | Eli Lilly And Company | Medication delivery device with sensing system |
| US10869967B2 (en) * | 2017-01-06 | 2020-12-22 | Verily Life Sciences Llc | Rigid sensor stopper for use in drug delivery devices |
| US10732270B2 (en) * | 2017-03-08 | 2020-08-04 | Verily Life Sciences Llc | Drug cartridge with acoustic reflector |
| US11497848B2 (en) * | 2017-04-03 | 2022-11-15 | Becton, Dickinson And Company | Systems and methods to detect catheter occlusion |
| JP7204688B2 (ja) * | 2017-06-09 | 2023-01-16 | サノフイ | 投与量検知用の電子機器 |
| US20190054252A1 (en) * | 2017-08-17 | 2019-02-21 | Qualcomm Incorporated | Optical methods for measuring dosage in a medicine delivery device |
| US20200230325A1 (en) | 2017-09-30 | 2020-07-23 | Novo Nordisk A/S | Cartridge system for a drug delivery device |
| DK3709888T3 (da) | 2017-11-14 | 2024-11-25 | Sanofi Sa | Integration af en ultralydssensor i en injektionsanordnings stempelstopper |
| CA3082658A1 (en) * | 2017-11-15 | 2019-05-23 | Desvac | Drug delivery apparatus |
| US11769578B2 (en) | 2017-12-21 | 2023-09-26 | Sanofi | Transmission of data associated with an injection device usage using passive RF modulation |
| CN111511422A (zh) * | 2017-12-28 | 2020-08-07 | 赛诺菲 | 剂量测量系统 |
| JP7307097B2 (ja) * | 2018-01-26 | 2023-07-11 | サノフイ | 注射用薬剤の容器 |
| JP7307098B2 (ja) | 2018-01-26 | 2023-07-11 | サノフイ | 注射用薬剤の容器 |
| US11197962B2 (en) * | 2018-02-26 | 2021-12-14 | Verily Life Sciences Llc | Waveform reconstruction for ultrasound time of flight measurements |
| US12608789B2 (en) | 2021-02-15 | 2026-04-21 | Amgen Inc. | Systems and methods for automated in-line plunger depth measurement |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980868A (en) * | 1973-11-02 | 1990-12-25 | The United States Of America As Represented By The Secretary Of The Navy | Sonar system |
| EP0104172B1 (de) * | 1982-03-30 | 1987-07-15 | REUTER, Martin | Einrichtung zur bestimmung eines relativabstands bei einer zylinder-kolben-einheit |
| US4811595A (en) * | 1987-04-06 | 1989-03-14 | Applied Acoustic Research, Inc. | System for monitoring fluent material within a container |
| US4936143A (en) * | 1989-04-28 | 1990-06-26 | Eaton Corporation | Cylinders having piston position measurement |
| US5241278A (en) * | 1991-07-05 | 1993-08-31 | Caterpillar Inc. | Radio frequency linear position sensor using two subsequent harmonics |
| JPH0783727A (ja) * | 1993-09-17 | 1995-03-31 | Nissan Motor Co Ltd | 容積計 |
| US5792117A (en) * | 1994-07-22 | 1998-08-11 | Raya Systems, Inc. | Apparatus for optically determining and electronically recording injection doses in syringes |
| US20030110967A1 (en) * | 2001-12-13 | 2003-06-19 | Mcanally Charles K. | Ink cartridge for ink level management apparatus |
| JP4286019B2 (ja) * | 2003-02-04 | 2009-06-24 | 株式会社根本杏林堂 | 薬液注入システム |
| JP4283170B2 (ja) * | 2003-12-17 | 2009-06-24 | 株式会社デンソー | 物体検出装置 |
| WO2005087109A1 (ja) * | 2004-03-12 | 2005-09-22 | Hitachi Medical Corporation | 超音波撮像装置 |
| JP5635723B2 (ja) * | 2006-01-30 | 2014-12-03 | 富士通株式会社 | 目標検出装置およびシステム |
| DE102006047537B4 (de) | 2006-10-07 | 2024-05-16 | Sanofi-Aventis Deutschland Gmbh | Verfahren und Vorrichtung zur Bestimmung der Position eines Stopfens einer Ampulle für ein Arzneimittel in einem medizinischen Gerät sowie deren Verwendung, ein entsprechendes medizinisches Gerät sowie Herstellung eines medizinischen Geräts |
| DE102007035252A1 (de) * | 2007-07-27 | 2009-02-12 | Truma Gerätetechnik GmbH & Co. KG | Vorrichtung zum Bestimmen der Position eines Kolbens in einem Zylinder |
| US20090031789A1 (en) * | 2007-08-02 | 2009-02-05 | Olympus Corporation | Liquid measuring device and automatic analyzer |
| JP2009195669A (ja) * | 2008-01-25 | 2009-09-03 | Canon Inc | 薬剤吐出装置及びその制御方法 |
| JP5613769B2 (ja) * | 2009-09-18 | 2014-10-29 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ストッパの長手位置を決定するための配置 |
| GB201015745D0 (en) * | 2010-09-21 | 2010-10-27 | Rolls Royce Goodrich Engine Co | Position sensor system |
| EP3400981B1 (en) * | 2011-09-08 | 2019-12-25 | Sanofi-Aventis Deutschland GmbH | Method and monitoring device for monitoring operaton of a drug delivery device |
| US9199380B2 (en) * | 2011-10-28 | 2015-12-01 | University Of Washington Through Its Center For Commercialization | Acoustic proximity sensing |
| US9592345B2 (en) * | 2012-07-11 | 2017-03-14 | Sanofi-Aventis Deutschland Gmbh | Arrangement and method for determining a stopper position |
-
2013
- 2013-07-10 US US14/413,631 patent/US9592345B2/en active Active
- 2013-07-10 DK DK13735038.5T patent/DK2872917T3/da active
- 2013-07-10 WO PCT/EP2013/064630 patent/WO2014009442A1/en not_active Ceased
- 2013-07-10 DK DK16180037.0T patent/DK3112896T3/da active
- 2013-07-10 CN CN201380036504.2A patent/CN104428688A/zh active Pending
- 2013-07-10 CN CN201910988074.3A patent/CN111007514A/zh active Pending
- 2013-07-10 EP EP16180037.0A patent/EP3112896B1/en active Active
- 2013-07-10 JP JP2015520980A patent/JP6266613B2/ja active Active
- 2013-07-10 EP EP13735038.5A patent/EP2872917B1/en active Active
-
2017
- 2017-03-13 US US15/456,960 patent/US10226578B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111007514A (zh) | 2020-04-14 |
| US20170182251A1 (en) | 2017-06-29 |
| HK1206432A1 (zh) | 2016-01-08 |
| EP3112896A1 (en) | 2017-01-04 |
| US10226578B2 (en) | 2019-03-12 |
| JP2015529481A (ja) | 2015-10-08 |
| WO2014009442A1 (en) | 2014-01-16 |
| US9592345B2 (en) | 2017-03-14 |
| EP3112896B1 (en) | 2019-10-09 |
| US20150174330A1 (en) | 2015-06-25 |
| JP6266613B2 (ja) | 2018-01-24 |
| DK3112896T3 (da) | 2020-01-06 |
| EP2872917A1 (en) | 2015-05-20 |
| EP2872917B1 (en) | 2016-08-31 |
| CN104428688A (zh) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2872917T3 (da) | Indretning og fremgangsmåde til bestemmelse af en propposition | |
| US20190365989A1 (en) | Method and Monitoring Device for Monitoring Operation of a Drug Delivery Device | |
| US20230390496A1 (en) | Container for an injectable medicament | |
| US20150209522A1 (en) | Drug delivery device and method for detecting contact between piston rod and cartridge bung via vibration excitation and monitoring | |
| US10564129B2 (en) | Method and arrangement for acoustically testing the mechanical integrity of a cartridge | |
| US20230241323A1 (en) | Container for an injectable medicament | |
| US20150238700A1 (en) | Method for Assembling a Drug Delivery Device | |
| HK1206432B (en) | Arrangement and method for determining a stopper position | |
| US11878146B2 (en) | Measurement probe for an injection device | |
| HK40111380A (en) | Container for an injectable medicament | |
| HK40036071A (en) | Container for an injectable medicament | |
| HK40036071B (en) | Container for an injectable medicament | |
| HK40040170A (en) | Measurement probe for an injection device |